FCF Life Sciences Venture Capital Monitor – 01/2020 published

FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Life Sciences Venture Capital Monitor – 01/2020”.

The Monitor is a monthly published overview of biotechnology, pharmaceutical, medical technology and healthcare technology companies, displaying venture capital financing trends in the European life sciences industry.

Key insights for January 2020 are:

  • With EUR 349m funding volume on par with January 2019
  • BioTech/Pharma with 56% of the funding volume well ahead
  • High-Tech Gründerfonds and Boehringer Ingelheim Venture among most active investors
  • Swiss, French and UK companies receive almost 75% of the investments

To access the full report, please click here.

By Dr. Mathias SchottSebastian Sommer and Elijah Falk

[a-zA-Z0-9_.-]
[a-zA-Z0-9_.-]
[a-zA-Z0-9]
[a-zA-Z0-9]